There is compelling evidence that interstitial inflammation plays a central role in the loss of renal function in chronic renal disease. The combined effects of interstitial inflammation, oxidative stress and local angiotensin II activity result in the disruption of glomerulus-tubule continuity, the development of pathogenic hypoxia, the generation of myofibroblasts and fibrosis, and the impairment of the protective autoregulation of glomerular blood flow that leads to glomerulosclerosis. The association between proteinuria and progression of chronic kidney disease is firmly established. Proximal tubular cells (PTC) exposed to high concentration of proteins produce proinflammatory and profibrotic factors. The activation of nuclear factor ĸB and the signal transducer and activator of transcription results in the upregulation of a variety of cytokines and chemokines, overexpression of adhesion molecules and interstitial infiltration of inflammatory cells. Fibrosis is promoted by release of transforming growth factor β, which induces myofibroblast formation and collagen deposition. Finally, the participation of vitamin D3 deficiency in the development of tubulointerstitial fibrosis is reviewed. The molecule 1,25-(OH)2D3 modulates PTC proliferation, suppresses fibroblast activation and matrix production, reduces epithelial mesenchymal transition and downregulates the genes of the renin-angiotensin system, which are critical steps in the development of a scarred kidney.

Keywords:
Inflammatory cells, Proteinuria, Chronic kidney disease, Oxidative stress, Atubular glomeruli, Vitamin D
1.
Risdon RA, Sloper JC, de Wardener HE: Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968;2:363–366.
2.
Bohle A, Mackensen-Haen S, von Gise H, Grund KE, Wehrmann M, Batz C, Bogenschütz O, Schmitt H, Nagy J, Müller C, Müller G: The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract 1990;186:135–144.
3.
Rodríguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ: The role of immunocompetent cells in non-immune renal diseases. Kidney Int 2001;59:1626–1640.
4.
Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Tubulointerstitial damage and progression of renal failure. Kidney Int 2005;68(suppl 99):S82–S86.
5.
Lin SL, Kisseleva T, Brenner DA, Duffield JS: Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008;173:1617–1627.
6.
Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341–350.
7.
Tan TK, Zheng G, Hsu TT, Wang Y, Lee VW, Tian X, Wang Y, Cao Q, Wang Y, Harris DC: Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells. Am J Pathol 2010, E-pub ahead of print.
8.
Liu Y: Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213–217.
9.
Kriz W, LeHir M: Pathways to nephron loss starting from glomerular diseases: insights from animal models. Kidney Int 2005;67:404–419.
10.
Benigni A, Gagliardini E, Remuzzi A, Coma D, Remuzzi G: Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heyman nephritis, an effect not observed with a calcium antagonist. Am J Pathol 2001;159:1743–1750.
11.
Gandhi M, Olson JL, Meyer TW: Contribution of tubular injury to loss of remnant kidney function. Kidney Int 1998;54:1157–1165.
12.
Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008;74:867–872.
13.
Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end stage renal failure. J Am Soc Nephrol 2006;17:17–25.
14.
Eddy AA: Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005;12:353–365.
15.
Miyata T, de Strihou CY: Diabetic nephropathy: a disorder of oxygen metabolism? Nat Rev Nephrol 2009;6:1–13.
16.
Bidani AK, Griffin KA: Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004;44:595–601.
17.
Salmond R, Seney FD: Reset tubuloglomerular feedback permits and sustains glomerular hyperfunction after extensive renal ablation. Am J Physiol 1991;260:F395–F401.
18.
Sánchez-Lozada G, Tapia E, Johnson RJ, Rodriguez-Iturbe B, Herrera-Acosta J: Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int 2003;64(suppl 86): S9–S14.
19.
Touyz RM, He G, El Mabroul M, Schiffrin EL: p38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension 2001;37:574–580.
20.
Sharma K, Cook A, Smith M, Valancius C, Inscho EW: TGF-beta impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 2005;288:F1069–F1077.
21.
Alvarez V, Quiroz Y, Nava M, Pons H, Rodriguez-Iturbe B: Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 2002;283:F1132–F1141.
22.
Remuzzi G: Nephropathic nature of proteinuria. Curr Opin Nephrol Hypertens 1999;8:655–663.
23.
D’Amico G, Bazzi C: Pathophysiology of proteinuria. Kidney Int 2003;63:809–825.
24.
Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003;63:1468–1474.
25.
Nakajima H, Takenaka M, Kaimori JY, Nagasawa Y, Kosugi A, Kawamoto S, Imai E, Hori M, Okubo K: Gene expression profile of renal proximal tubules regulated by proteinuria. Kidney Int 2002;61:1577–1587.
26.
Biemesderfer D: Regulated intramembrane proteolysis of megalin: linking urinary protein and gene regulation in proximal tubule? Kidney Int 2006;69:1717–1721.
27.
Morigi M, Macconi D, Zoja C, Donadelli R, Buelli S, Zanchi C, Ghilardi M, Remuzzi G: Protein overload-induced NF-ĸB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. J Am Soc Nephrol 2002;13:1179–1189.
28.
Takase O, Hirahashi J, Takayanagi A, Chikaraishi A, Marumo T, Ozawa Y, Hayashi M, Shimizu N, Saruta T: Gene transfer of truncated IĸBα prevents tubulointerstitial injury. Kidney Int 2003;63:501–513.
29.
Anders HJ, Ninichuk V, Schöndorff D: Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int 2006;69:29–32.
30.
He C, Imai M, Song H, Quigg RJ, Tomlinson S: Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephritic syndrome and demonstrate a key role for C5b-9. J Immunol 2005;174:5750–5757.
31.
Noris M, Morigi M, Remuzzi B: Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. J Am Soc Nephrol 2008;19:1158–1167.
32.
Van Timmeren MM, Bakker SJ, Stegeman CA, Gans RO, van Goor H: Addition of oleic acid to delipidated bovine serum albumin aggravates renal damage in experimental protein-overload nephrosis. Nephrol Dial Transplant 2005;20:2349–2357.
33.
Arici M, Chana R, Lewington A, Brown J, Brunskill NJ: Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptor-γ. J Am Soc Nephrol 2003;14:17–27.
34.
Morais C, Westhuyzen J, Metharom P, Healy H: High molecular weight plasma proteins induce apoptosis and Fas/FasL expression in human proximal tubular cells. Nephrol Dial Transplant 2005;20:50–58.
35.
Tejera N, Gomez-Garre D, Lazaro A, Gallego-Delgado J, Alonso C, Blanco J, Ortiz A, Egido J: Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. Am J Pathol 2004;164:1817–1826.
36.
Macconi D, Chiabrando C, Schiarea S, Aiello S, Cassis L, Gagliardini E, Noris M, Buelli S, Zoja C, Corna D, Mele C, Fanelli R, Remuzzi G, Benigni A: Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol 2009;20:123–130.
37.
Weinreich Z, Müller A, Wüthrich RP, Booy C, Binswanger U: 1,25-Dihydroxyvitamin D3 and the synthetic vitamin D analogue, KH 1060, modulate the growth of mouse proximal tubular cells. Kidney Blood Press Res 1996;19:325–331.
38.
Li Y, Spataro BC, Yang J, Dai C, Liu Y: 1,25-Dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005;68:1500–1510.
39.
Aschenbrenner JK, Sollinger HW, Becker BN, Hullet DA: 1,25-(OH)2D3 alters the transforming growth factor β signaling pathway in renal tissue. J Surg Res 2001;100:171–175.
40.
Tan X, He W, Liu Y: Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int 2009;76:1248–1257.
41.
Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B: Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394–1402.
42.
Kikuchi H, Kawachi H, Ito Y, et al: Severe proteinuria, sustained for 6 months, induces tubular epithelial cell injury and cell infiltration in rats but not progressive interstitial fibrosis. Nephrol Dial Transplant 2000;15:799–810.
43.
Wahlstedt-Fröberg V, Pettersson T, Aminoff M, Dugué B, Gräsbeck R: Proteinuria in cubilin-deficient patients with selective vitamin B12 malabsorption. Pediatr Nephrol 2003;18:417–421.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.